PDF herunterladen
Semin Neurol 2015; 35(04): 448-457
DOI: 10.1055/s-0035-1558977
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Toxic Neuropathies

Chafic Karam
1   Department of Neurology, The University of North Carolina at Chapel Hill, North Carolina
,
P. James B. Dyck
2   Department of Neurology, Mayo Clinic, Rochester, Minnesota
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
06. Oktober 2015 (online)

    Lizenzen und Reprints

Abstract

Toxic neuropathies are a rare, but important cause of acquired polyneuropathy. In this review article, the authors discuss the general principles of toxic neuropathies and provide a systematic review of neuropathies related to drugs, heavy metals, environmental and industrial agents, and alcoholic neuropathies.

Keywords

acquired neuropathy - toxic neuropathy - drug toxicity - heavy metals - industrial agents - alcohol
 

  • References

  • 1 Diouf B, Crews KR, Lew G , et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA 2015; 313 (8) 815-823
    CrossrefPubMedGoogle Scholar
  • 2 Johnson DC, Corthals SL, Walker BA , et al. Genetic factors underlying the risk of thalidomide-related neuropathy in patients with multiple myeloma. J Clin Oncol 2011; 29 (7) 797-804
    CrossrefPubMedGoogle Scholar
  • 3 Mauermann ML, Blumenreich MS, Dispenzieri A, Staff NP. A case of peripheral nerve microvasculitis associated with multiple myeloma and bortezomib treatment. Muscle Nerve 2012; 46 (6) 970-977
    CrossrefPubMedGoogle Scholar
  • 4 Verstappen CC, Koeppen S, Heimans JJ , et al. Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 2005; 64 (6) 1076-1077
    CrossrefPubMedGoogle Scholar
  • 5 Kuwabara S, Kai MR, Nagase H, Hattori T. n-Hexane neuropathy caused by addictive inhalation: clinical and electrophysiological features. Eur Neurol 1999; 41 (3) 163-167
    CrossrefPubMedGoogle Scholar
  • 6 Glendenning JL, Barbachano Y, Norman AR, Dearnaley DP, Horwich A, Huddart RA. Long-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer. Cancer 2010; 116 (10) 2322
    PubMedGoogle Scholar
  • 7 LoPachin RM, Ross JF, Lehning EJ. Nerve terminals as the primary site of acrylamide action: a hypothesis. Neurotoxicology 2002; 23 (1) 43-59
    CrossrefPubMedGoogle Scholar
  • 8 Hill AB. The environment and disease: association or causation? Proceedings of the Royal Society of Medicine. Proc R Soc Med 1965; 58 (5) 295-300
    PubMedGoogle Scholar
  • 9 Albers JW, Chaudhry V, Cavaletti G, Donehower RC. Interventions for preventing neuropathy caused by cisplatin and related compounds. Cochrane Database Syst Rev 2014; 3: CD005228
    PubMedGoogle Scholar
  • 10 Casey EB, Jellife AM, Le Quesne PM, Millett YL. Vincristine neuropathy. Clinical and electrophysiological observations. Brain 1973; 96 (1) 69-86
    CrossrefPubMedGoogle Scholar
  • 11 Pal PK. Clinical and electrophysiological studies in vincristine induced neuropathy. Electromyogr Clin Neurophysiol 1999; 39 (6) 323-330
    PubMedGoogle Scholar
  • 12 Freilich RJ, Balmaceda C, Seidman AD, Rubin M, DeAngelis LM. Motor neuropathy due to docetaxel and paclitaxel. Neurology 1996; 47 (1) 115-118
    CrossrefPubMedGoogle Scholar
  • 13 Lehky TJ, Leonard GD, Wilson RH, Grem JL, Floeter MK. Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy. Muscle Nerve 2004; 29 (3) 387-392
    CrossrefPubMedGoogle Scholar
  • 14 Richardson PG, Briemberg H, Jagannath S , et al. Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006; 24 (19) 3113-3120
    CrossrefPubMedGoogle Scholar
  • 15 Broyl A, Corthals SL, Jongen JL , et al. Mechanisms of peripheral neuropathy associated with bortezomib and vincristine in patients with newly diagnosed multiple myeloma: a prospective analysis of data from the HOVON-65/GMMG-HD4 trial. Lancet Oncol 2010; 11 (11) 1057-1065
    CrossrefPubMedGoogle Scholar
  • 16 Plasmati R, Pastorelli F, Cavo M , et al. Neuropathy in multiple myeloma treated with thalidomide: a prospective study. Neurology 2007; 69 (6) 573-581
    CrossrefPubMedGoogle Scholar
  • 17 Chaudhry V, Cornblath DR, Corse A, Freimer M, Simmons-O'Brien E, Vogelsang G. Thalidomide-induced neuropathy. Neurology 2002; 59 (12) 1872-1875
    CrossrefPubMedGoogle Scholar
  • 18 Giannini F, Volpi N, Rossi S, Passero S, Fimiani M, Cerase A. Thalidomide-induced neuropathy: a ganglionopathy?. Neurology 2003; 60 (5) 877-878
    CrossrefPubMedGoogle Scholar
  • 19 Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro-oncol 2012; 14 (Suppl. 04) iv45-iv54
    PubMedGoogle Scholar
  • 20 Etminan M, Brophy JM, Samii A. Oral fluoroquinolone use and risk of peripheral neuropathy: a pharmacoepidemiologic study. Neurology 2014; 83 (14) 1261-1263
    CrossrefPubMedGoogle Scholar
  • 21 Ali AK. Peripheral neuropathy and Guillain-Barré syndrome risks associated with exposure to systemic fluoroquinolones: a pharmacovigilance analysis. Ann Epidemiol 2014; 24 (4) 279-285
    CrossrefPubMedGoogle Scholar
  • 22 Zivkovic SA, Lacomis D. Severe sensory neuropathy associated with long-term linezolid use. Neurology 2005; 64 (5) 926-927
    CrossrefPubMedGoogle Scholar
  • 23 Joy RJ, Scalettar R, Sodee DB. Optic and peripheral neuritis. Probable effect of prolonged chloramphenicol therapy. JAMA 1960; 173: 1731-1734
    CrossrefPubMedGoogle Scholar
  • 24 McCarty M. How clinically relevant is dapsone-related peripheral neuropathy?: An overview of available data with emphasis on clinical recognition. J Clin Aesthet Dermatol 2010; 3 (3) 19-21
    PubMedGoogle Scholar
  • 25 Geyer HL, Herskovitz S, Slamovits TL, Schaumburg HH. Optochiasmatic and peripheral neuropathy due to ethambutol overtreatment. J Neuroophthalmol 2014; 34 (3) 257-258
    CrossrefPubMedGoogle Scholar
  • 26 Tan CH, Chen YF, Chen CC, Chao CC, Liou HH, Hsieh ST. Painful neuropathy due to skin denervation after metronidazole-induced neurotoxicity. J Neurol Neurosurg Psychiatry 2011; 82 (4) 462-465
    CrossrefPubMedGoogle Scholar
  • 27 Tan IL, Polydefkis MJ, Ebenezer GJ, Hauer P, McArthur JC. Peripheral nerve toxic effects of nitrofurantoin. Arch Neurol 2012; 69 (2) 265-268
    CrossrefPubMedGoogle Scholar
  • 28 Steichen O, Martinez-Almoyna L, De Broucker T. [Isoniazid induced neuropathy: consider prevention]. Rev Mal Respir 2006; 23 (2 Pt 1) 157-160
    PubMedGoogle Scholar
  • 29 Brew BJ, Tisch S, Law M. Lactate concentrations distinguish between nucleoside neuropathy and HIV neuropathy. AIDS 2003; 17 (7) 1094-1096
    CrossrefPubMedGoogle Scholar
  • 30 Estes ML, Ewing-Wilson D, Chou SM , et al. Chloroquine neuromyotoxicity. Clinical and pathologic perspective. Am J Med 1987; 82 (3) 447-455
    CrossrefPubMedGoogle Scholar
  • 31 Orr CF, Ahlskog JE. Frequency, characteristics, and risk factors for amiodarone neurotoxicity. Arch Neurol 2009; 66 (7) 865-869
    PubMedGoogle Scholar
  • 32 Erdem S, Freimer ML, O'Dorisio T, Mendell JR. Procainamide-induced chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1998; 50 (3) 824-825
    CrossrefPubMedGoogle Scholar
  • 33 Raskin NH, Fishman RA. Pyridoxine-deficiency neuropathy due to hydralazine. N Engl J Med 1965; 273 (22) 1182-1185
    CrossrefPubMedGoogle Scholar
  • 34 Said G. Perhexiline neuropathy: a clinicopathological study. Ann Neurol 1978; 3 (3) 259-266
    CrossrefPubMedGoogle Scholar
  • 35 Gaist D, Jeppesen U, Andersen M, García Rodríguez LA, Hallas J, Sindrup SH. Statins and risk of polyneuropathy: a case-control study. Neurology 2002; 58 (9) 1333-1337
    CrossrefPubMedGoogle Scholar
  • 36 Tierney EF, Thurman DJ, Beckles GL, Cadwell BL. Association of statin use with peripheral neuropathy in the U.S. population 40 years of age or older. J Diabetes 2013; 5 (2) 207-215
    CrossrefPubMedGoogle Scholar
  • 37 Frisoni GB, Di Monda V. Disulfiram neuropathy: a review (1971–1988) and report of a case. Alcohol Alcohol 1989; 24 (5) 429-437
    PubMedGoogle Scholar
  • 38 Shorvon SD, Reynolds EH. Anticonvulsant peripheral neuropathy: a clinical and electrophysiological study of patients on single drug treatment with phenytoin, carbamazepine or barbiturates. J Neurol Neurosurg Psychiatry 1982; 45 (7) 620-626
    CrossrefPubMedGoogle Scholar
  • 39 Albin RL, Albers JW, Greenberg HS , et al. Acute sensory neuropathy-neuronopathy from pyridoxine overdose. Neurology 1987; 37 (11) 1729-1732
    CrossrefPubMedGoogle Scholar
  • 40 Schlumpf U, Meyer M, Ulrich J, Friede RL. Neurologic complications induced by gold treatment. Arthritis Rheum 1983; 26 (7) 825-831
    CrossrefPubMedGoogle Scholar
  • 41 Kuncl RW, Duncan G, Watson D, Alderson K, Rogawski MA, Peper M. Colchicine myopathy and neuropathy. N Engl J Med 1987; 316 (25) 1562-1568
    CrossrefPubMedGoogle Scholar
  • 42 Kuo HC, Huang CC, Tsai YT, Chu CC, Hsieh ST, Chu NS. Acute painful neuropathy in thallium poisoning. Neurology 2005; 65 (2) 302-304
    CrossrefPubMedGoogle Scholar
  • 43 Rubens O, Logina I, Kravale I, Eglîte M, Donaghy M. Peripheral neuropathy in chronic occupational inorganic lead exposure: a clinical and electrophysiological study. J Neurol Neurosurg Psychiatry 2001; 71 (2) 200-204
    CrossrefPubMedGoogle Scholar
  • 44 Thomson RM, Parry GJ. Neuropathies associated with excessive exposure to lead. Muscle Nerve 2006; 33 (6) 732-741
    CrossrefPubMedGoogle Scholar
  • 45 Donofrio PD, Wilbourn AJ, Albers JW, Rogers L, Salanga V, Greenberg HS. Acute arsenic intoxication presenting as Guillain-Barré-like syndrome. Muscle Nerve 1987; 10 (2) 114-120
    CrossrefPubMedGoogle Scholar
  • 46 Feldman RG, Niles CA, Kelly-Hayes M , et al. Peripheral neuropathy in arsenic smelter workers. Neurology 1979; 29 (7) 939-944
    CrossrefPubMedGoogle Scholar
  • 47 Albers JW, Cavender GD, Levine SP, Langolf GD. Asymptomatic sensorimotor polyneuropathy in workers exposed to elemental mercury. Neurology 1982; 32 (10) 1168-1174
    CrossrefPubMedGoogle Scholar
  • 48 Chu CC, Huang CC, Ryu SJ, Wu TN. Chronic inorganic mercury induced peripheral neuropathy. Acta Neurol Scand 1998; 98 (6) 461-465
    CrossrefPubMedGoogle Scholar
  • 49 Huang CC, Chu CC, Wu TN, Shih TS, Chu NS. Clinical course in patients with chronic carbon disulfide polyneuropathy. Clin Neurol Neurosurg 2002; 104 (2) 115-120
    CrossrefPubMedGoogle Scholar
  • 50 Kuo HC, Huang CC, Chu CC, Chu NS. Axonal polyneuropathy after acute dimethylamine borane intoxication. Arch Neurol 2006; 63 (7) 1009-1012
    CrossrefPubMedGoogle Scholar
  • 51 Reddy NJ, Sudini M, Lewis LD. Delayed neurological sequelae from ethylene glycol, diethylene glycol and methanol poisonings. Clin Toxicol (Phila) 2010; 48 (10) 967-973
    CrossrefPubMedGoogle Scholar
  • 52 Herskowitz A, Ishii N, Schaumburg H. N-hexane neuropathy. A syndrome occurring as a result of industrial exposure. N Engl J Med 1971; 285 (2) 82-85
    CrossrefPubMedGoogle Scholar
  • 53 Spencer PS, Schaumburg HH. Nervous system degeneration produced by acrylamide monomer. Environ Health Perspect 1975; 11: 129-133
    CrossrefPubMedGoogle Scholar
  • 54 Davenport JG, Farrell DF, Sumi M. “Giant axonal neuropathy” caused by industrial chemicals: neurofilamentous axonal masses in man. Neurology 1976; 26 (10) 919-923
    CrossrefPubMedGoogle Scholar
  • 55 LeWitt PA. The neurotoxicity of the rat poison vacor. A clinical study of 12 cases. N Engl J Med 1980; 302 (2) 73-77
    CrossrefPubMedGoogle Scholar
  • 56 Moretto A, Lotti M. Poisoning by organophosphorus insecticides and sensory neuropathy. J Neurol Neurosurg Psychiatry 1998; 64 (4) 463-468
    CrossrefPubMedGoogle Scholar
  • 57 Kaplan JG, Kessler J, Rosenberg N, Pack D, Schaumburg HH. Sensory neuropathy associated with Dursban (chlorpyrifos) exposure. Neurology 1993; 43 (11) 2193-2196
    CrossrefPubMedGoogle Scholar
  • 58 Albers JW, Garabrant DH, Schweitzer S, Garrison RP, Richardson RJ, Berent S. Absence of sensory neuropathy among workers with occupational exposure to chlorpyrifos. Muscle Nerve 2004; 29 (5) 677-686
    CrossrefPubMedGoogle Scholar
  • 59 Butera R, Prockop LD, Buonocore M, Locatelli C, Gandini C, Manzo L. Mild ciguatera poisoning: case reports with neurophysiological evaluations. Muscle Nerve 2000; 23 (10) 1598-1603
    CrossrefPubMedGoogle Scholar
  • 60 Fernández-Fígares M, Fernández V, Postigo MJ, Feron P. Acute paralysis after seafood ingestion. Neurophysiol Clin 2013; 43 (5-6) 299-302
    CrossrefPubMedGoogle Scholar
  • 61 Salazar-Leal ME, Flores MS, Sepulveda-Saavedra J , et al. An experimental model of peripheral neuropathy induced in rats by Karwinskia humboldtiana (buckthorn) fruit. J Peripher Nerv Syst 2006; 11 (3) 253-261
    CrossrefPubMedGoogle Scholar
  • 62 Lachance DH, Lennon VA, Pittock SJ , et al. An outbreak of neurological autoimmunity with polyradiculoneuropathy in workers exposed to aerosolised porcine neural tissue: a descriptive study. Lancet Neurol 2010; 9 (1) 55-66
    CrossrefPubMedGoogle Scholar
  • 63 Grattan-Smith PJ, Morris JG, Johnston HM , et al. Clinical and neurophysiological features of tick paralysis. Brain 1997; 120 (Pt 11): 1975-1987
    CrossrefPubMedGoogle Scholar
  • 64 Hadfield TL, McEvoy P, Polotsky Y, Tzinserling VA, Yakovlev AA. The pathology of diphtheria. J Infect Dis 2000; 181 (Suppl. 01) S116-S120
    CrossrefPubMedGoogle Scholar
  • 65 Koike H, Iijima M, Sugiura M , et al. Alcoholic neuropathy is clinicopathologically distinct from thiamine-deficiency neuropathy. Ann Neurol 2003; 54 (1) 19-29
    CrossrefPubMedGoogle Scholar